Scholars@Duke
Andrew John Armstrong

Andrew John Armstrong

George Barth Geller Distinguished Professor for Research in Cancer
Medicine, Medical Oncology
andrew.armstrong@duke.edu
Duke Box 103861, Durham, NC 27710
GSRB1 Room 3006, 905 La Salle St, Durham, NC 27710
Office hours

Scholarly Works - Other

Data from <i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial

Other · December 15, 2025 <div>AbstractPurpose:<p>Low-density lipoprotein receptor–related protein 1b (<i>LRP1b</i>) is a cell surface receptor, commonly altered in many cancers and associated with improved responses, progression-free survival (PFS), ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · November 25, 2025 <p>Percent PSMA expression positivity (PSMA+CTC x 100/ Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · November 25, 2025 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · November 25, 2025 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · November 25, 2025 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · November 25, 2025 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · November 25, 2025 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · November 25, 2025 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · November 25, 2025 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Data from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

Other · November 1, 2024 <div>AbstractPurpose:<p>Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced o ... Full text Cite

Figure 2 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Other · October 18, 2024 <p>Stronger IFN-β responses to TLR1/2 stimulation associates with longer survival after sip-T therapy. <b>A,</b> HRs ± 95% CIs from a Cox proportional hazards model comparing induction of each cytokine (fold mock control) after TL ... Full text Cite

Figure 3 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Other · October 18, 2024 <p>IFN-β induction after TLR1/2 stimulation associates with PBMC ELISpot responses to Fluzone, PHA, and CEFT (cytomegalovirus, EBV, Fluzone, and Tetanus peptide pool). <b>A,</b> ELISpot SFU after each indicated stimulant (<i&gt ... Full text Cite

Figure 1 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Other · October 18, 2024 <p>Study design and <i>in vitro</i> responsiveness of PBMCs from patients with mCRPC to PRR agonist prior to sip-T treatment. <b>A,</b> Banked pretreatment PBMCs from the PRIME sip-T discovery cohort (<i>n</i& ... Full text Cite

Figure 5 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Other · October 18, 2024 <p>TLR1/2 responses associate with post–sip-T survival independent of race and TLR1/2 SNP status. <b>A–C,</b> Survival stratified by race in the merged PRIME and KCI cohorts (<b>A</b>), PRIME cohort alone (<b>B&l ... Full text Cite

Data from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Other · October 18, 2024 <div>Abstract<p>Mounting evidence links systemic innate immunity with cancer immune surveillance. In advanced metastatic castration-resistant prostate cancer (mCRPC), Black patients have been found to have increased inflammatory markers ... Full text Cite

Figure 4 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Other · October 18, 2024 <p>Black race and TLR1-602I SNP associate with stronger responses to TLR1/2 stimulation. <b>A,</b> Supernatant cytokine release separated by Black (<i>n</i> = 15) vs. White (<i>n</i> = 91) for each stimulat ... Full text Cite

Supplementary Table S2 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Other · March 15, 2024 <p>Association of CTC HOXB13 expression with overall survival, univariate and multivariate analysis including adjustment for JHU CTC AR-V7 status</p> ... Full text Cite

Supplementary Table S2 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Other · March 15, 2024 <p>Association of CTC HOXB13 expression with overall survival, univariate and multivariate analysis including adjustment for JHU CTC AR-V7 status</p> ... Full text Cite

Data from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Other · March 15, 2024 <div>AbstractPurpose:<p>HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated ... Full text Cite

Data from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Other · March 15, 2024 <div>AbstractPurpose:<p>HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated ... Full text Cite

Supplementary Figure S1 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Figure S1: Supplementary Figure S1 showing study schema for xaluritamig intravenous monotherapy dose exploration and expansion phases.</p> ... Full text Cite

Supplementary Figure S1 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Figure S1: Supplementary Figure S1 showing study schema for xaluritamig intravenous monotherapy dose exploration and expansion phases.</p> ... Full text Cite

Data from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <div>Abstract<p>Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer ... Full text Cite

Supplementary Methods from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Methods: Additional methodology including full inclusion criteria, full exclusion criteria, and definition of dose-limiting toxicities.</p> ... Full text Cite

Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Figure S2: Supplementary Figure S2 swimlane plot showing time on treatment for xaluritamig patients in low-dose cohorts.</p> ... Full text Cite

Supplementary Table S1 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Table S1: Supplementary Table S1 showing representativeness of study patients, including age, race/ethnicity, geography, other considerations, and overall representativeness of this study.</p> ... Full text Cite

Supplementary Table S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Table S2: Supplementary Table S2 showing antidrug antibody (ADA) impact to landmark prostate-specific antigen response (PSA50) at 12 weeks.</p> ... Full text Cite

Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Figure S2: Supplementary Figure S2 swimlane plot showing time on treatment for xaluritamig patients in low-dose cohorts.</p> ... Full text Cite

Supplementary Table S1 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Table S1: Supplementary Table S1 showing representativeness of study patients, including age, race/ethnicity, geography, other considerations, and overall representativeness of this study.</p> ... Full text Cite

Supplementary Table S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Table S2: Supplementary Table S2 showing antidrug antibody (ADA) impact to landmark prostate-specific antigen response (PSA50) at 12 weeks.</p> ... Full text Cite

Data from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <div>Abstract<p>Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer ... Full text Cite

Supplementary Methods from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Other · January 12, 2024 <p>Supplementary Methods: Additional methodology including full inclusion criteria, full exclusion criteria, and definition of dose-limiting toxicities.</p> ... Full text Cite

Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <div>AbstractPurpose:<p>In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizi ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>Percent PSMA expression positivity (PSMA+CTC x 100/ Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <div>AbstractPurpose:<p>In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizi ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · May 15, 2023 <p>Percent PSMA expression positivity (PSMA+CTC x 100/ Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>Percent PSMA expression positivity (PSMA+CTC x 100/ Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <div>AbstractPurpose:<p>In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizi ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>Percent PSMA expression positivity (PSMA+CTC x 100/ Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 12, 2023 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>Percent PSMA expression positivity (PSMA+CTC x 100/Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>Percent PSMA expression positivity (PSMA+CTC x 100/Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <div>AbstractPurpose:<p>In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizi ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · April 4, 2023 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Data from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <div>Abstract<p>Men with circulating tumor cell (CTC) AR-V7–positive metastatic castration-resistant prostate cancer (mCRPC) have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and ... Full text Cite

Figure S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Comprehensive copy number alterations analysis in CTC DNA. The heat map represents the copy number alterations of sixty genes in (A) 45 baseline and (B) 28 progression CTCs DNA samples at individual patient-level. Genomic copy gain is pres ... Full text Cite

Figure S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Visualization of reference vs. alternate alleles in baseline vs. progression CTCs DNA. All the COSMIC validated mutations uniquely detected in baseline and paired progression CTCs DNA was visualized in the IGV genome browser with sequence ... Full text Cite

File S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Top somatic COSMIC variations were compared between 11 baselines and matched post-treatment CTC-DNA of mCRPC patients. Matched WBC DNA has been used as a reference control for somatic mutation. All the somatic mutations detected in CTCs DN ... Full text Cite

Figure S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Comprehensive copy number alterations analysis in CTC DNA. The heat map represents the copy number alterations of sixty genes in (A) 45 baseline and (B) 28 progression CTCs DNA samples at individual patient-level. Genomic copy gain is pres ... Full text Cite

File S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>The table representing the top somatic mutations validated in the COSMIC database were compared between baseline sensitive (N=5) and resistant CTC-DNA (N=5).</p> ... Full text Cite

File S2 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Commonly altered genes present in >=40% of progression cases (N=28).</p> ... Full text Cite

Figure S2 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Copy number alterations validations in independent publically available clinical datasets. (A) and (B) illustrating the top CTCs DNA genomic alterations were independently validated in 1115 patients from 1154 metastatic prostate cancer bio ... Full text Cite

Figure S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Visualization of reference vs. alternate alleles in baseline vs. progression CTCs DNA. All the COSMIC validated mutations uniquely detected in baseline and paired progression CTCs DNA was visualized in the IGV genome browser with sequence ... Full text Cite

Table S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Top pathways enriched at baseline (N=45) and progression (N=28) during ingenuity pathway analysis (IPA, Qiagen). Selection criteria; top genes altered in >=40% of the cases.</p> ... Full text Cite

Figure S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Comparing copy number alterations in CTCs DNA over time. A heat map shows the copy number alterations of sixty genes in 25 paired baseline and progression CTCs DNA, longitudinally at individual patient-level. Genomic copy gain is presented ... Full text Cite

File S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>The table representing the copy number and mutation data together for all 11 baseline and paired progression CTCs DNA samples.</p> ... Full text Cite

Figure S2 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Copy number alterations validations in independent publically available clinical datasets. (A) and (B) illustrating the top CTCs DNA genomic alterations were independently validated in 1115 patients from 1154 metastatic prostate cancer bio ... Full text Cite

Figure S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Comparing copy number alterations in CTCs DNA over time. A heat map shows the copy number alterations of sixty genes in 25 paired baseline and progression CTCs DNA, longitudinally at individual patient-level. Genomic copy gain is presented ... Full text Cite

Figure S6 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Visualization of reference vs. alternate alleles in sensitive vs. resistant CTCs DNA. All the COSMIC validated mutations uniquely detected in sensitive and resistant CTCs DNA was visualized in the IGV genome browser with sequence read dept ... Full text Cite

File S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>The table representing the top somatic mutations validated in the COSMIC database were compared between baseline sensitive (N=5) and resistant CTC-DNA (N=5).</p> ... Full text Cite

File S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>The table representing the copy number and mutation data together for all 11 baseline and paired progression CTCs DNA samples.</p> ... Full text Cite

Figure S6 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Visualization of reference vs. alternate alleles in sensitive vs. resistant CTCs DNA. All the COSMIC validated mutations uniquely detected in sensitive and resistant CTCs DNA was visualized in the IGV genome browser with sequence read dept ... Full text Cite

File S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Top somatic COSMIC variations were compared between 11 baselines and matched post-treatment CTC-DNA of mCRPC patients. Matched WBC DNA has been used as a reference control for somatic mutation. All the somatic mutations detected in CTCs DN ... Full text Cite

Figure S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Genomic-wide CNAs analysis in CTCs in the radium-223 trial. Top genomic gain (A) and loss (B) detected in the PROPHECY trial were independently validated in the radium-223 trial CTCs DNA (N=14 patients) study. Before radium-223 treatment, ... Full text Cite

Table S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Top pathways enriched at baseline (N=45) and progression (N=28) during ingenuity pathway analysis (IPA, Qiagen). Selection criteria; top genes altered in >=40% of the cases.</p> ... Full text Cite

Figure S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Genomic-wide CNAs analysis in CTCs in the radium-223 trial. Top genomic gain (A) and loss (B) detected in the PROPHECY trial were independently validated in the radium-223 trial CTCs DNA (N=14 patients) study. Before radium-223 treatment, ... Full text Cite

File S2 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <p>Commonly altered genes present in >=40% of progression cases (N=28).</p> ... Full text Cite

Data from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Other · April 3, 2023 <div>Abstract<p>Men with circulating tumor cell (CTC) AR-V7–positive metastatic castration-resistant prostate cancer (mCRPC) have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text Cite

Figure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>Percent PSMA expression positivity (PSMA+CTC x 100/Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Other · March 31, 2023 <div>AbstractPurpose:<p>While the detection of AR-V7 in circulating tumor cells (CTC) is associated with resistance to abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), it only accounts for ... Full text Cite

Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>Percent PSMA expression positivity (PSMA+CTC x 100/Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Figure S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, N= 57) abiraterone or enzalutamide therapy.</p> ... Full text Cite

Data from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <div>AbstractPurpose:<p>In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizi ... Full text Cite

Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Other · March 31, 2023 <div>AbstractPurpose:<p>While the detection of AR-V7 in circulating tumor cells (CTC) is associated with resistance to abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), it only accounts for ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p> ... Full text Cite

Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.</p> ... Full text Cite

Table S1 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.</p> ... Full text Cite

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Other · March 31, 2023 <p>A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group be ... Full text Cite

Supplementary Figure 3 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <p>Supplementary Figure 3. Kaplan-Meier OS curves by dichotomized angiokines: VEGF-D, VEGF, VEGF-R1, PDGF-AA, TGF-b1, VEGF-R3, HER-3, BMP-9, CD-73, VEGF-R2, TGF-b2, SDF-1, PDGF-BB, and TGFb-R3</p> ... Full text Cite

Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <p>Supplementary Figure 4A. Kaplan-Meier PFS curves by treatment and dichotomized angiokines groups for following angiokines: TGFb-R3, HGF, TSP-2, OPN, IL-6, SDF-1, Ang-2, ICAM-1, TGF-b2, TIMP-1, BMP-9, PDGF-BB, VCAM-1, PDGF-AA, VEGF-D, TGF-b ... Full text Cite

Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <p>Supplementary Figure 4A. Kaplan-Meier PFS curves by treatment and dichotomized angiokines groups for following angiokines: TGFb-R3, HGF, TSP-2, OPN, IL-6, SDF-1, Ang-2, ICAM-1, TGF-b2, TIMP-1, BMP-9, PDGF-BB, VCAM-1, PDGF-AA, VEGF-D, TGF-b ... Full text Cite

Supplementary Figure 4B from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <p>Supplementary Figure 4B Kaplan-Meier OS curves by treatment and dichotomized angiokines groups for following angiokines: TGFb-R3, HGF, TSP-2, OPN, IL-6, SDF-1, Ang-2, ICAM-1, TGF-b2, TIMP-1, BMP-9, PDGF-BB, VCAM-1, PDGF-AA, VEGF-D, TGF-b1, ... Full text Cite

Supplementary Figure 2 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <p>Supplementary Figure 2. Kaplan-Meier PFS curves by dichotomized angiokines: CD-73, BMP-9, VEGF-R1, PDGF-BB, VEGF, IL-6, VCAM-1, OPN, HGF, PDGF-AA, TGFb-R3, TGF-b1, VEGF-R3, and TGF-b2</p> ... Full text Cite

Supplementary Figure 3 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <p>Supplementary Figure 3. Kaplan-Meier OS curves by dichotomized angiokines: VEGF-D, VEGF, VEGF-R1, PDGF-AA, TGF-b1, VEGF-R3, HER-3, BMP-9, CD-73, VEGF-R2, TGF-b2, SDF-1, PDGF-BB, and TGFb-R3</p> ... Full text Cite

Supplementary Figure 4B from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <p>Supplementary Figure 4B Kaplan-Meier OS curves by treatment and dichotomized angiokines groups for following angiokines: TGFb-R3, HGF, TSP-2, OPN, IL-6, SDF-1, Ang-2, ICAM-1, TGF-b2, TIMP-1, BMP-9, PDGF-BB, VCAM-1, PDGF-AA, VEGF-D, TGF-b1, ... Full text Cite

Supplementary Figure 2 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <p>Supplementary Figure 2. Kaplan-Meier PFS curves by dichotomized angiokines: CD-73, BMP-9, VEGF-R1, PDGF-BB, VEGF, IL-6, VCAM-1, OPN, HGF, PDGF-AA, TGFb-R3, TGF-b1, VEGF-R3, and TGF-b2</p> ... Full text Cite

Data from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <div>AbstractPurpose:<p>Biomarkers are needed in patients with non–clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating angiokines ... Full text Cite

Data from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

Other · March 31, 2023 <div>AbstractPurpose:<p>Biomarkers are needed in patients with non–clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating angiokines ... Full text Cite

Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Other · March 31, 2023 Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial ... Full text Cite

Data from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Other · March 31, 2023 <div>AbstractPurpose:<p>The clinical impact of concurrent corticosteroid use (CCU) on enzalutamide-treated patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. We investigated the association of CCU with ove ... Full text Cite

Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Other · March 31, 2023 Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial ... Full text Cite

Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Other · March 31, 2023 Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial ... Full text Cite

Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Other · March 31, 2023 Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial ... Full text Cite

Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Other · March 31, 2023 Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer ... Full text Cite

Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Other · March 31, 2023 Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial ... Full text Cite

Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Other · March 31, 2023 <div>AbstractPurpose:<p>A phase Ib study (1604) was conducted to evaluate the safety and efficacy of GS-5829, an oral bromodomain and extraterminal inhibitor, alone and in combination with enzalutamide in metastatic castration-resistant ... Full text Cite

Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Other · March 31, 2023 Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial ... Full text Cite

Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Other · March 31, 2023 <div>AbstractPurpose:<p>A phase Ib study (1604) was conducted to evaluate the safety and efficacy of GS-5829, an oral bromodomain and extraterminal inhibitor, alone and in combination with enzalutamide in metastatic castration-resistant ... Full text Cite

Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Other · March 31, 2023 Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer ... Full text Cite

Data from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Other · March 31, 2023 <div>AbstractPurpose:<p>The clinical impact of concurrent corticosteroid use (CCU) on enzalutamide-treated patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. We investigated the association of CCU with ove ... Full text Cite

Abstract SS02-02: A long walk from FGFR2 alternative splicing to cancer progression

Other Cancer Epidemiology, Biomarkers & Prevention · November 1, 2014 AbstractPreviously, our group developed fluorescence-based alternative splicing reporters of epithelial plasticity to visualize phenotypic transitions in real time in vivo (Oltean et al., 2008; Oltean et al. ... Full text Cite

What to order from the prostate cancer treatment menu?

Other Oncology (Williston Park) · January 2012 Link to item Cite